The DNA Damage Transducer RNF8 Facilitates Cancer Chemoresistance and Progression through Twist Activation
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Twist has been shown to cause treatment failure, cancer progression and cancer-related death. However, strategies that directly target Twist are not yet conceivable. Here we revealed K63-linked ubiquitination is a crucial regulatory mechanism for Twist activation. Through an E3 ligase screen and biochemical studies, we unexpectedly identified that RNF8 functions as a direct Twist activator by triggering K63-linked ubiquitination of Twist. RNF8-promoted Twist ubiquitination is required for Twist localization to the nucleus for subsequent EMT and CSC functions, thereby conferring chemoresistance. Our histological analyses showed that RNF8 expression is upregulated and correlated with disease progression, EMT features and poor patient survival in breast cancer. Moreover, RNF8 regulates cancer cell migration and invasion and cancer metastasis, recapitulating the effect of Twist. Together, our findings reveal a previously unrecognized tumor-promoting function of RNF8 and provide the first evidence that targeting RNF8 is an appealing strategy to tackle tumor aggressiveness and treatment resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091 · cited 1×
“Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer that exhibits an overall poor outcome with current dose-dense chemotherapy regimens (Andre and Zielinski, 2012; Dent et al., 2007).”
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 1×
“In contrast, progress toward dramatic improvements in long-term survival and tumor eradication, particularly for metastatic patients, remains disappointing (Holohan et al., 2013).”
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545 · cited 1×
“Cancer stem cells (CSCs) are intrinsically quiescent and highly resistant to chemotherapy (Singh and Settleman, 2010).”
Fischer, K. R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S. T. C., Choi, H., El Rayes, T., Ryu, S., Troeger, J., et al. (2015) · Nature · doi:10.1038/nature15748 · Cited by 1,791
Direct regulation of TWIST by HIF-1α promotes metastasis
Yang, M.-H., Wu, M.-Z., Chiou, S.-H., Chen, P.-M., Chang, S.-Y., Liu, C.-J., Teng, S.-C., & Wu, K.-J. (2008) · Nature Cell Biology · doi:10.1038/ncb1691 · Cited by 1,345
Non-histone protein methylation as a regulator of cellular signalling and function
Biggar, K. K., & Li, S. S.-C. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3915 · Cited by 479 · cited 1×
“Methylation of lysine residues on non-histone proteins has emerged as a prevalent post-translational modification and as an important regulator of signal transduction in cells (Biggar and Li, 2015).”
Chan, C.-H., Morrow, J. K., Li, C.-F., Gao, Y., Jin, G., Moten, A., Stagg, L. J., Ladbury, J. E., Cai, Z., Xu, D., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.048 · Cited by 391 · cited 1×
“The fact that these ubiquitination-controlling enzymes are deregulated in diseases, including cancer, has made them attractive as potential drug targets (Chan et al., 2013; Hoeller and Dikic, 2009; Skaar et al., 2014).”
Self-citationStructural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability
Surade, S., & Blundell, T. L. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.013 · Cited by 230 · cited 2×
“However, the development of pharmacological agents to specifically target Twist and other EMT-TFs is lagging because of the lack of a ligand binding domain in them (Surade and Blundell, 2012), creating a need for the identification of more druggable targets for EMT-based therapy.”
The E3 ubiquitin ligase Rnf8 stabilizes Tpp1 to promote telomere end protection.
Rai, R., Li, J.-M., Zheng, H., Lok, G. T.-M., Deng, Y., Huen, M. S.-Y., Chen, J., Jin, J., & Chang, S. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2172 · Cited by 88
Cited by
Epithelial-Mesenchymal Transition and Metastasis under the Control of Transforming Growth Factor β
Tsubakihara, Y., & Moustakas, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113672 · Cited by 160
van Staalduinen, J., Baker, D., ten Dijke, P., & van Dam, H. (2018) · Oncogene · doi:10.1038/s41388-018-0378-x · Cited by 158
CBP mediated DOT1L acetylation confers DOT1L stability and promotes cancer metastasis
Liu, C., Yang, Q., Zhu, Q., Lu, X., Li, M., Hou, T., Li, Z., Tang, M., Li, Y., Wang, H., et al. (2020) · Theranostics · doi:10.7150/thno.39013 · Cited by 62
Metadata
- Authors
- Lee, H.-J., Li, C.-F., Ruan, D., Powers, S., Thompson, P. A., Frohman, M. A., & Chan, C.-H.
- Venue
- Molecular Cell
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 63
- Issue
- 6
- Pages
- 1021-1033
- ISSN
- 1097-2765 (ISSN-L)
- OpenAlex
- W2519186861
- Cited by
- 116
- References
- 10
- FWCI
- 4.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The DNA Damage Transducer RNF8 Facilitates Cancer Chemoresistance and Progression through Twist Activation. https://app.cochat.ai/papers/10.1016/j.molcel.2016.08.009
- The paper
- Lee, H.-J., Li, C.-F., Ruan, D., Powers, S., Thompson, P. A., Frohman, M. A., & Chan, C.-H. (2016). The DNA Damage Transducer RNF8 Facilitates Cancer Chemoresistance and Progression through Twist Activation. Molecular Cell. https://doi.org/10.1016/j.molcel.2016.08.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.